Michael Glen Kauffman MD PhD
Rheumatology
CEO, Karyopharm Therapeutics Inc.
Join to view full profile
326 Mattison DrConcord, MA 01742
Phone+1 978-369-6079
Fax+1 978-369-0343
Dr. Kauffman is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Mass General Brigham/Massachusetts General HospitalFellowship, Rheumatology, 1994 - 1997
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 1992 - 1994
Johns Hopkins University School of MedicineClass of 1992
Certifications & Licensure
MA State Medical License 1994 - 2028
FL State Medical License 2024 - 2027
American Board of Internal Medicine Internal Medicine
Publications & Presentations
PubMed
- 29 citationsFunctional Genome-wide Screening Identifies Targets and Pathways Sensitizing Pancreatic Cancer Cells to Dasatinib.Wenwen Chien, Makoto Sudo, Ling-Wen Ding, Qiao-Yang Sun, Peer Wuensche
Journal of Cancer. 2018-12-10 - 14 citationsDown-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression.Amro Aboukameel, Irfana Muqbil, Erkan Baloglu, William Senapedis, Yosef Landesman
Oncotarget. 2018-10-19 - 50 citationsSelinexor reduces the expression of DNA damage repair proteins and sensitizes cancer cells to DNA damaging agentsTrinayan Kashyap, Christian Argueta, Thaddeus J. Unger, Boris Klebanov, Sophia A. Debler
Oncotarget. 2018-07-20
Abstracts/Posters
- Response to Therapy and the Effectiveness of Treatment with Selinexor and Dexamethasone in Patients with Penta-Exposed Triple-Class Refractory Myeloma Who Had Plasmacy...Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined An...Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1b/2 Study of Selinexor, Carfilzomib, and Dexamethasone (SKd) in Relapsed/ Refractory Multiple Myeloma (RRMM)Michael G. Kauffman, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Lectures
- Single Agent Oral Selinexor Demonstrates Deep and Durable Responses in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) in Both GCB and Non-GCB Subtypes: The ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Oncology Drugs Fast-Tracked by the FDA in May and June 2026July 1st, 2026- Verastem Oncology Appoints Paul Bunn, M.D., and Lesley Solomon to Board of DirectorsJune 24th, 2021
- Karyopharm Announces Upcoming Virtual Investor Conference ParticipationFebruary 17th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
